Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Johnson and Johnson
Medtronic
Moodys

Last Updated: June 28, 2022

ORAVIG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Oravig, and when can generic versions of Oravig launch?

Oravig is a drug marketed by Galt Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-four patent family members in fourteen countries.

The generic ingredient in ORAVIG is miconazole. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole profile page.

DrugPatentWatch® Generic Entry Outlook for Oravig

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 11, 2022. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for ORAVIG
Drug patent expirations by year for ORAVIG
Drug Prices for ORAVIG

See drug prices for ORAVIG

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ORAVIG
Generic Entry Date for ORAVIG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;BUCCAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ORAVIG

US Patents and Regulatory Information for ORAVIG

ORAVIG is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ORAVIG is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ORAVIG

Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS

Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS

Prolonged release bioadhesive therapeutic systems
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galt Pharms ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Galt Pharms ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Galt Pharms ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ORAVIG

See the table below for patents covering ORAVIG around the world.

Country Patent Number Title Estimated Expiration
Israel 159842 SUSTAINED-RELEASE THERAPEUTIC BIOADHESIVE SYSTEMS See Plans and Pricing
Cyprus 1107828 See Plans and Pricing
European Patent Office 1792610 Systèmes thérapeutiques bioadhésifs à libération prolongée (Sustained release bioadhesive therapeutic systems) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
McKinsey
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.